IMNNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Imunon, Inc.
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Aug 11, 2026
$0.98−0.04 (-3.43%)
Close on Oct 19, 2026
- Market cap
- $4.95M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
5.7%
0M of 6M shares
Institutional holders
23
6 new, 2 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 6 sales
Net sold $38.13K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Steven Boyd | 450,315 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| Armistice Capital, LLC | 349,917 | 9.99% | 13G (passive) | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of IMNN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 144,767 | 2.58% | $257.69K | −203,563 | 0.00% |
| Vanguard Capital Management LLC | 46,967 | 0.84% | $83.60K | −1,089 | 0.00% |
| Riverview Capital Advisers, LLC | 34,364 | 0.61% | $247.77K | – | 0.07% |
| Geode Capital Management, LLC | 31,629 | 0.56% | $56.30K | −1,582 | 0.00% |
| Virtu Financial LLC | 17,456 | 0.31% | $31 | New | 0.00% |
| Vanguard Fiduciary Trust Co | 13,269 | 0.24% | $23.62K | – | 0.00% |
| Northern Trust Corp | 10,342 | 0.18% | $18.41K | New | 0.00% |
| UBS Group AG | 5,203 | 0.09% | $9.26K | +4,628 | 0.00% |
| BlackRock, Inc. | 4,464 | 0.08% | $7.95K | – | 0.00% |
| Tower Research Capital LLC (TRC) | 3,952 | 0.07% | $7.04K | +2,086 | 0.00% |
| Wells Fargo & Company/Mn | 3,342 | 0.06% | $5.95K | – | 0.00% |
| Morgan Stanley | 1,574 | 0.03% | $2.80K | −1,461 | 0.00% |
| SBI Securities Co., Ltd. | 1,027 | 0.02% | $1.83K | – | 0.00% |
| Barclays PLC | 194 | 0.00% | $345 | New | 0.00% |
| JPMorgan Chase & Co | 134 | 0.00% | $241 | New | 0.00% |
| Caitong International Asset Management Co., Ltd | 8 | 0.00% | $14 | New | 0.00% |
| Group One Trading, L.P. | 6 | 0.00% | $11 | – | 0.00% |
| Northwestern Mutual Wealth Management Co | 3 | 0.00% | $5 | New | 0.00% |
| Osaic Holdings, Inc. | 2 | 0.00% | $3 | – | 0.00% |
| Steigerwald, Gordon & Koch Inc. | 1 | 0.00% | $2 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 23 | 0M | 5.7% | 6 / 2 | 4 / 2 | 0M | 0M |
| Q1 2026 | 19 | 1M | 9.0% | 3 / 6 | 3 / 3 | 0M | 0M |
| Q4 2025 | 20 | 0M | 7.7% | 3 / 4 | 6 / 0 | 0M | 0M |
| Q3 2025 | 17 | 0M | 2.8% | 16 / 0 | 1 / 0 | 0M | 0M |
| Q2 2025 | 1 | 0M | 0.2% | 1 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of IMNN | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 46,967 | 0.84% | $83.60K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 20,413 | 0.36% | $44.50K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 4,744 | 0.08% | $10.34K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 1,776 | 0.03% | $3.87K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 163 | 0.00% | $355 | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Stacy Lindborg | President and CEO, Director | 113,975 | 2.03% | Sep 28, 2026 |
| Michael H. Tardugno | Executive Chairman of Board, Director | 108,543 | 1.93% | Sep 28, 2026 |
| Douglas Vincent Faller | Chief Medical Officer | 45,678 | 0.81% | Sep 28, 2026 |
| Susan Eylward | General Counsel and Corp Sec | 2,896 | 0.05% | Sep 1, 2026 |
| Joshua Blacher | CFO | – | – | Jul 7, 2026 |
| Jeffrey Wayne Church | CFO | 26 | 0.00% | Jan 20, 2026 |
| Kimberly Bragg | CFO | 20,400 | 0.36% | Jan 6, 2026 |
| Khursheed Anwer | Chief Scientific Officer | 5,000 | 0.09% | Jan 6, 2026 |
| Christine A. Pellizzari | Director | 15,076 | 0.27% | Aug 4, 2026 |
| Frederick J. Fritz | Director | 39,081 | 0.70% | Aug 4, 2026 |
| James E. Dentzer | Director | 21,897 | 0.39% | Aug 4, 2026 |
| Donald P. Braun | Director | 15,499 | 0.28% | Aug 4, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Stacy Lindborg President and CEO, Director | Sep 25, 2026 | Award | +6,697 | $1.41 | $9.44K | 113,197 |
| Douglas Vincent Faller Chief Medical Officer | Sep 25, 2026 | Award | +4,390 | $1.41 | $6.19K | 45,678 |
| Michael H. Tardugno Executive Chairman of Board, Director | Sep 25, 2026 | Award | +7,169 | $1.41 | $10.11K | 103,921 |
| Stacy Lindborg President and CEO, Director | Sep 11, 2026 | Award | +5,504 | $1.47 | $8.09K | 105,580 |
| Michael H. Tardugno Executive Chairman of Board, Director | Sep 11, 2026 | Award | +5,824 | $1.47 | $8.56K | 95,699 |
| Douglas Vincent Faller Chief Medical Officer | Sep 11, 2026 | Award | +4,211 | $1.47 | $6.19K | 41,288 |
| Susan Eylward General Counsel and Corp Sec | Aug 31, 2026 | Sale | −2,525 | $1.56 | $3.94K | 2,896 |
| Susan Eylward General Counsel and Corp Sec | Aug 28, 2026 | Award | +2,525 | $1.60 | $4.04K | 5,421 |
| Michael H. Tardugno Executive Chairman of Board, Director | Aug 28, 2026 | Award | +7,371 | $1.60 | $11.79K | 89,875 |
| Stacy Lindborg President and CEO, Director | Aug 28, 2026 | Award | +6,822 | $1.60 | $10.92K | 100,076 |
| Douglas Vincent Faller Chief Medical Officer | Aug 28, 2026 | Award | +3,626 | $1.60 | $5.80K | 37,077 |
| Susan Eylward General Counsel and Corp Sec | Aug 17, 2026 | Sale | −2,449 | $1.63 | $3.99K | 2,896 |
| Michael H. Tardugno Executive Chairman of Board, Director | Aug 14, 2026 | Award | +7,147 | $1.65 | $11.79K | 82,504 |
| Susan Eylward General Counsel and Corp Sec | Aug 14, 2026 | Award | +2,449 | $1.65 | $4.04K | 5,345 |
| Stacy Lindborg President and CEO, Director | Aug 14, 2026 | Award | +6,615 | $1.65 | $10.91K | 93,254 |
| Douglas Vincent Faller Chief Medical Officer | Aug 14, 2026 | Award | +3,516 | $1.65 | $5.80K | 33,451 |
| Susan Eylward General Counsel and Corp Sec | Aug 3, 2026 | Sale | −2,541 | $1.57 | $3.99K | 2,896 |
| Christine A. Pellizzari Director | Jul 31, 2026 | Award | +6,934 | $1.59 | $11.03K | 15,076 |
| Stacy Lindborg President and CEO, Director | Jul 31, 2026 | Award | +5,010 | $1.59 | $7.97K | 86,639 |
| Donald P. Braun Director | Jul 31, 2026 | Award | +6,180 | $1.59 | $9.83K | 15,499 |
| Frederick J. Fritz Director | Jul 31, 2026 | Award | +6,934 | $1.59 | $11.03K | 21,031 |
| Susan Eylward General Counsel and Corp Sec | Jul 31, 2026 | Award | +2,541 | $1.59 | $4.04K | 5,437 |
| James E. Dentzer Director | Jul 31, 2026 | Award | +6,934 | $1.59 | $11.03K | 21,897 |
| Douglas Vincent Faller Chief Medical Officer | Jul 31, 2026 | Award | +3,649 | $1.59 | $5.80K | 29,935 |
| Michael H. Tardugno Executive Chairman of Board, Director | Jul 31, 2026 | Award | +6,358 | $1.59 | $10.11K | 75,357 |
| Susan Eylward General Counsel and Corp Sec | Jul 20, 2026 | Sale | −2,150 | $1.78 | $3.83K | 2,896 |
| Stacy Lindborg President and CEO, Director | Jul 17, 2026 | Award | +4,907 | $1.83 | $8.98K | 81,629 |
| Michael H. Tardugno Executive Chairman of Board, Director | Jul 17, 2026 | Award | +4,603 | $1.83 | $8.42K | 68,999 |
| Douglas Vincent Faller Chief Medical Officer | Jul 17, 2026 | Award | +3,082 | $1.83 | $5.64K | 26,286 |
| Susan Eylward General Counsel and Corp Sec | Jul 17, 2026 | Award | +2,150 | $1.83 | $3.93K | 5,046 |
| Susan Eylward General Counsel and Corp Sec | Jul 6, 2026 | Sale | −920 | $1.88 | $1.73K | 2,896 |
| Susan Eylward General Counsel and Corp Sec | Jul 2, 2026 | Award | +920 | $1.91 | $1.76K | 3,816 |
| Stacy Lindborg President and CEO, Director | Jul 2, 2026 | Award | +2,534 | $1.91 | $4.84K | 76,722 |
| Michael H. Tardugno Executive Chairman of Board, Director | Jul 2, 2026 | Award | +4,410 | $1.91 | $8.42K | 64,396 |
| Douglas Vincent Faller Chief Medical Officer | Jul 2, 2026 | Award | +1,308 | $1.91 | $2.50K | 23,204 |
| Susan Eylward General Counsel and Corp Sec | Jun 29, 2026 | Sale | −11,800 | $1.75 | $20.65K | 2,896 |
| Douglas Vincent Faller Chief Medical Officer | Jun 25, 2026 | Award | +21,896 | $1.72 | $37.66K | 21,896 |
| Stacy Lindborg President and CEO, Director | Jun 25, 2026 | Award | +67,150 | $1.72 | $115.50K | 74,188 |
| Susan Eylward General Counsel and Corp Sec | Jun 25, 2026 | Award | +14,696 | $1.72 | $25.28K | 14,696 |
| Michael H. Tardugno Executive Chairman of Board, Director | Jun 25, 2026 | Award | +42,519 | $1.72 | $73.13K | 59,986 |
| Michael H. Tardugno Executive Chairman of Board, Director | Jun 18, 2026 | Award | +4,629 | $1.82 | $8.42K | 17,467 |
| Stacy Lindborg President and CEO, Director | Jun 18, 2026 | Award | +1,803 | $1.82 | $3.28K | 7,038 |
| Michael H. Tardugno Executive Chairman of Board, Director | Jun 5, 2026 | Award | +4,089 | $2.06 | $8.42K | 12,838 |
| Stacy Lindborg President and CEO, Director | Jun 5, 2026 | Award | +1,593 | $2.06 | $3.28K | 5,235 |
| Frederick J. Fritz Director | May 22, 2026 | Award | +10,330 | $2.20 | $22.73K | 14,097 |
| Donald P. Braun Director | May 22, 2026 | Award | +5,011 | $2.20 | $11.02K | 9,319 |
| Michael H. Tardugno Executive Chairman of Board, Director | May 22, 2026 | Award | +3,484 | $2.20 | $7.66K | 8,749 |
| Christine A. Pellizzari Director | May 22, 2026 | Award | +5,557 | $2.20 | $12.23K | 8,142 |
| James E. Dentzer Director | May 22, 2026 | Award | +11,148 | $2.20 | $24.53K | 14,963 |
| Stacy Lindborg President and CEO, Director | May 22, 2026 | Award | +1,491 | $2.20 | $3.28K | 3,642 |
| Stacy Lindborg President and CEO, Director | Sep 6, 2025 | Option exercise | +1,667 | – | – | 3,584 |
| Christine A. Pellizzari Director | Aug 4, 2025 | Award | +2,248 | $9.20 | $20.68K | 2,248 |
| James E. Dentzer Director | Aug 4, 2025 | Award | +3,318 | $9.20 | $30.53K | 3,318 |
| Frederick J. Fritz Director | Aug 4, 2025 | Award | +3,161 | $9.20 | $29.08K | 3,946 |
| Donald P. Braun Director | Aug 4, 2025 | Award | +2,040 | $9.20 | $18.77K | 3,747 |
| Donald P. Braun Director | Aug 20, 2024 | Buy | +25,000 | $1.18 | $29.50K | 25,597 |
| Stacy Lindborg President and CEO, Director | Aug 15, 2024 | Buy | +25,000 | $0.98 | $24.50K | 264,166 |
| Michael H. Tardugno Executive Chairman of Board, Director | Aug 15, 2024 | Buy | +25,000 | $1.03 | $25.75K | 353,346 |
| Sebastien Hazard Chief Medical Officer | Dec 7, 2023 | Award | +20,000 | – | – | 20,000 |
| Goff Corinne Le President and CEO, Director | Jul 18, 2022 | Award | +53,000 | – | – | 53,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.